| Title : Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease - Scheltens_2026_Alzheimers.Dement.(N.Y)_12_e70200 |
| Author(s) : Scheltens P , Atri A , Feldman HH , Zetterberg H , Sano M , Johannsen P , Colombo TL , Bardtrum L , Jeppesen R , Hansen CT , Cummings JL |
| Ref : Alzheimers Dement (N Y) , 12 :e70200 , 2026 |
| Abstract : |
| PubMedSearch : Scheltens_2026_Alzheimers.Dement.(N.Y)_12_e70200 |
| PubMedID: 41522368 |
| Title : Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease - Scheltens_2026_Alzheimers.Dement.(N.Y)_12_e70200 |
| Author(s) : Scheltens P , Atri A , Feldman HH , Zetterberg H , Sano M , Johannsen P , Colombo TL , Bardtrum L , Jeppesen R , Hansen CT , Cummings JL |
| Ref : Alzheimers Dement (N Y) , 12 :e70200 , 2026 |
| Abstract : |
| PubMedSearch : Scheltens_2026_Alzheimers.Dement.(N.Y)_12_e70200 |
| PubMedID: 41522368 |
| Title : Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo-controlled trials of semaglutide in participants with early-stage symptomatic Alzheimer's disease - Scheltens_2026_Alzheimers.Dement.(N.Y)_12_e70200 |
| Author(s) : Scheltens P , Atri A , Feldman HH , Zetterberg H , Sano M , Johannsen P , Colombo TL , Bardtrum L , Jeppesen R , Hansen CT , Cummings JL |
| Ref : Alzheimers Dement (N Y) , 12 :e70200 , 2026 |
| Abstract : |
| PubMedSearch : Scheltens_2026_Alzheimers.Dement.(N.Y)_12_e70200 |
| PubMedID: 41522368 |